Ablexis, LLC – Trademark Portfolio
Entity Type: 16
Ablexis, LLC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ABLEXIS and ALIVAMAB. The owner is based in San Diego, CA.
Suite 115
10581 Roselle Street
San Diego, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
Ablexis, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Ablexis, LLC have?
Ablexis, LLC has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 5 abandoned.
What trademark classes does Ablexis, LLC file in?
Ablexis, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Ablexis, LLC's most well-known trademarks?
Ablexis, LLC's registered trademark portfolio includes well-known marks such as ABLEXIS and ALIVAMAB. These are among 2 currently registered trademarks in the portfolio.
What is Ablexis, LLC's trademark registration success rate?
Ablexis, LLC has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.